Teleflex Incorporated (TFX) Earnings Call Transcript & Summary

October 28, 2021

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 60 min

Earnings Call Speaker Segments

Larry Keusch

executive
#1

Hello, everyone, and thanks for joining the Teleflex Incorporated Third Quarter 2021 Earnings Conference Call this morning. You can find the press release and the slides that go with this call on our website, teleflex.com. Please note that this call is being webcast on our site, and a replay can be accessed by calling (800) 585 to 8367, or if you're outside the U.S., (416) 621 to 4642, and entering passcode 4079822. On the call with us today are Liam Kelly, our Chairman, President and Chief Executive Officer, and Thomas Powell, our Executive Vice President and Chief Financial Officer. Liam and Tom are going to give prepared remarks, and after that, we'll take your questions in the Q&A session. Before we get started, I want to remind everyone that certain matters we'll discuss on this conference call will include forward-looking statements about future events, as described in our slides. We caution you that these statements are forward-looking in nature and involve risks and uncertainties, and actual events or results could differ materially. Factors that might cause actual results or events to differ materially include, but are not limited to, those referenced in today's press release and in our filings with the SEC, including our Form 10-K, which you can access on our website. During this conference call, you'll hear management discuss intra-quarter business performance. Management is offering this commentary to give the investment community additional insights into trends, and these disclosures might not be made in later quarters. With that, I'll hand the call over to Liam for his remarks.

Liam Kelly

executive
#2

Thanks, Larry, and good morning to all of you. I'm glad to have this chance to talk with you today; during Q3, Teleflex delivered constant currency revenue growth in the double digits along with a 27% rise in adjusted earnings per share compared with the prior year, even though we faced a bigger hit than anticipated from rising COVID-19 infections tied to the Delta variant. Every one of our worldwide product families posted year-over-year constant currency growth, aside from our other category, which was affected by the sale of the respiratory assets to Medline. Even though macro trends shifted away from what we had expected back in the second quarter, Teleflex's strong results in the third quarter of 2021 demonstrate how diversified our business is, along with the advantages of our wide-ranging portfolio of medically necessary products and our leadership across categories. The pressure on product revenues linked to elective surgery that faced pauses during Q3 was helped by our 6 main product families and extensive global footprint. As a lot of investors know, during the third quarter, restrictions were placed on elective surgical procedures in up to 28 states. Even so, what we've seen from the pandemic's beginning is that our diversified portfolio serves as a cushion whenever COVID cases climb, because more than 60% of our operations either benefit from increased COVID treatment volumes or remain relatively insulated from pandemic-driven interruptions. While providing updates mid-quarter isn't something we normally do, the delta variant's infection spike exceeded our forecasts, so I want to share a few specifics regarding Q3. Relative to the outlook we provided in our Q2 earnings report, we saw a larger-than-expected slowdown in elective surgeries within certain regions spanning the U.S., Europe and Asia. Even so, once coronavirus case counts fell, sales volume per day for the items most closely linked to planned operations began bouncing back over the course of September. Across the third quarter, every one of our segments — the Americas, EMEA, Asia and OEM — demonstrated staying power, and all of them posted revenue gains in constant currency versus 2020 despite pressure from the delta variant. This, as I mentioned before, underscores how much our broad product lineup is worth. Gross margin and operating margin for the third quarter landed higher than what we saw in the comparable stretches of both 2020 and 2019. Because our margins have kept widening throughout 2021, we've been able to channel more targeted spending into the areas that drive growth — something central to our longer-range plan for building lasting expansion. As we work to finish the year, we expect some modest improvement in the fourth quarter relative to the third quarter, while recognizing that the macro environment still isn't where we thought it would be when the year began. We're staying mindful of uncertainty surrounding COVID-19 infections as colder weather arrives in the Northern Hemisphere, along with new variants and shortages of health care workers. So we think the sensible approach is to plan on COVID-19 continuing to act as a headwind, and we don't see a widespread rebound in elective surgical procedure volumes back to normal levels happening in Q4. Our expectation is that these factors will prove temporary, and we look for a more normalized setting to take hold in 2022. Based on what we've delivered so far this year and how we see the fourth quarter shaping up, we're bringing our constant currency revenue growth down to 8% to 9%, compared with 8.5% to 9.75% before. What's mainly behind this change to the constant currency growth outlook is softer growth expectations for products tied to elective surgical procedures. That said, because our operating margin performance has been strong and our balance sheet has improved, we're raising EPS guidance to $13.15 to $13.35, up from the prior range of $12.90 to $13.10, which works out to 23% to 25% growth year-over-year. Now let's go through our third quarter results in more detail. Q3 revenue came in at $700.3 million, up 10.3% year-over-year on a constant currency basis. During that three-month stretch, revenue climbed compared to the prior year, which demonstrates what our varied lineup of businesses brings us, and growth arrived from every segment, though the pandemic's effects along with the sale of the respiratory assets to Medline worked against those gains; looking at the equivalent quarter in 2019, sales were up 5.8% and we saw quarter-over-quarter momentum building in Vascular, OEM and Anesthesia, which balanced out a step-down from one quarter to the next in areas hit harder by the COVID-19 spike, such as Interventional Urology, Interventional and Surgical. Results for the quarter on both growth and operating margin beat what we had projected, thanks to the resilience of our diversified portfolio, partially counterbalanced by pandemic-related pressures that proved larger than we had modeled. The way our margins have performed through this point in the year gives us reason for optimism about our profitability goals over the longer term. For the third quarter, adjusted earnings per share came in at $3.51, which was up 26.7% compared with the same period a year earlier and ahead of what we had forecast internally. Although the impact of COVID-19 on our adjusted earnings per share in the third quarter proved a bigger obstacle than we had expected, the improvement versus last year's third quarter shows the benefits of a more diversified lineup of products, slight increases in pricing, a higher gross margin, and operating expense control that came in better than we anticipated. We continue to carry out our plan of generating lasting growth by putting money into opportunities for organic expansion, innovation in our products, further margin gains, and using capital to pay down debt on our balance sheet as well as pursue M&A. It makes me proud to see how the team continues to perform under difficult circumstances. Looking at how we performed financially in Q3, you can see the strength of our broad worldwide product lineup, plus the focused spending we've directed toward areas that drive expansion, such as UroLift and MANTA — and this also shows we're moving closer to the margin goals we've set for the longer term. Now I'd like to dig further into the revenue figures. First, I'll walk through results by our reportable segments. Unless I say otherwise, every growth rate I mention is stated on a constant currency basis. In the Americas, we brought in $417.3 million during the third quarter, an increase of 10.9% compared with the same period a year ago. The segments pushing that year-over-year improvement were Surgical, Vascular and Interventional, though this was partly offset by delays in elective surgical procedures. In EMEA, we brought in $143.9 million, which was up 3.6% compared to the same period last year, with Interventional and Vascular products driving most of that expansion. The region got a lift from an easier COVID-19 comparison, since procedure volumes improved versus a year ago as nations throughout the area kept reopening even with some COVID-19-related interruptions. Now shifting to Asia. Revenue came to $75 million, a 6.3% rise year-over-year. Japan posted a robust third quarter, expanding beyond 30%, though COVID-19's effect in Southeast Asia partly offset that. Let's turn now to reviewing our third quarter revenues across global product categories. Building on my earlier remarks regarding our reportable segments, I'll now cover how each global product category grew—also on a constant currency basis, and arranged from our largest business unit to the smallest. One quick note: when we compare selling days in Q3, the year-over-year difference wasn't significant. Starting off with Vascular Access. Revenue for the quarter climbed 8.5%, coming in at $175.5 million. Because we lead the market in central venous catheters and midlines, and because of our coated PICC lineup's innovative design, we remain well positioned to grow consistently. Treating COVID-19 patients still depends heavily on what our Vascular Access portfolio offers, and that drove momentum during the third quarter as infection rates from the coronavirus went up. Solid performance continues to come from our PICC portfolio, which grew 10% compared with the same period last year. We remain committed to investing behind our differentiated PICC portfolio and are gaining market share.

Liam Kelly

executive
#3

Intraosseous had a solid Q3 as well, coming in 12% higher than the equivalent quarter a year ago. Moving along to Interventional: third-quarter revenue reached $104.3 million, up 10.4% from the prior-year period. Despite a spike in COVID-19 infections that tempered the pace of complex PCI and TAVR procedures, our execution remained strong in Q3. We continue to invest in our interventional portfolio, which spans complex catheters along with MANTA, our large-bore closure device. Momentum for MANTA remains powerful both domestically and in overseas markets, generating more than 80% growth globally versus the same quarter last year. Given the results MANTA has delivered during this year, our confidence remains high that we can capture an 8% share during 2021, within a global opportunity worth between $200 million and $300 million. Turning next to Anesthesia. Revenue for the third quarter came in at $97.1 million, up 26.6% compared with the same period a year earlier. Roughly 85% of that expansion was generated by Z-Medica's offerings, with this unit still tracking toward the $60 million to $70 million in revenue we expect for 2021, though lower tracheostomy product sales partly offset the gain. Within our Surgical segment, revenue came to $92.8 million, reflecting 10.9% growth versus the prior-year period. Looking at our largest product segments, ligation clips and instruments posted solid sales gains, driven by a more favorable elective surgery backdrop compared with the prior-year period, though the Delta variant weighed on results in select regions. Turning to Interventional Urology, Q3 revenue came in at $83.1 million, a 1.5% increase from a year earlier, which fell short of the guidance we gave on our quarter 2 conference call. During this quarter we were hurt by elective procedure cancellations related to state restrictions and ICU capacity constraints as Delta variant infections surged in parts of the U.S., plus continued pandemic-related business disruption. We continue to monitor UroLift trends closely. What's key here is that when we looked at billing claims for both commercial and Medicare over the last six months, the picture is clear: UroLift is still the number one procedure, and it hasn't lost ground to other minimally invasive BPH treatments. COVID-19 remains the single largest thing weighing on UroLift utilization, and on top of that, staffing shortages in physician offices are creating disruptions for the business. Both of these, in our view, are temporary, and we expect things to move back toward normal in 2022. Strong clinical data continue to drive preference for UroLift — research shows symptoms ease and patients recover quickly, sexual function stays intact with nothing new sustained, and the results hold up over time. Our analysis actually shows that hardly any of our seasoned users recommend alternative technologies for treating BPH, since they trust UroLift so much. Other device-based BPH treatments remain separate from the UroLift system, and we intend to keep our number one spot in day surgery treatments for this condition. We continue to go after patients dealing with BPH who either didn't succeed with drug therapy or aren't happy with it — a group we estimate at 1.5 million men across the United States. As we look toward the fourth quarter of 2021, we're assuming a macro environment that's pretty stable compared with what September brought, which reflects ongoing COVID-19 strain on elective surgical procedures. Taking into account softer-than-expected UroLift sales in Q3 and our updated Q4 forecast, our 2021 Interventional Urology revenue growth guidance is being reduced to a range of 15% to 17% compared with last year. For 2022, we anticipate elective surgical procedures returning to a more normal environment. Physician engagement continues to give us confidence, which we see through our active users, training of new physicians, and the ability to perform UroLift procedures in every relevant care setting. In the third quarter, our OEM business—about 9% of total sales—rose 29.4% year-over-year, reaching $64.1 million. Demand from our OEM customers is stabilizing, and that segment continues to show momentum. Our market position remains solid, since customers recognize the value of what we offer in design and manufacturing. Turning to our remaining category, it covers respiratory items that stayed with us after the Medline divestiture, along with manufacturing service agreement revenue and Urology Care products. That category came in at $83.4 million, down 4.3% compared with the same period last year. Most of that drop stems from revenue we no longer receive because the respiratory products were divested, though manufacturing service agreement revenue and Urology Care growth made up for part of it. Our expectation is unchanged that manufacturing service agreement revenue will wind down by the close of 2023. That wraps up what I wanted to say about how revenue performed in the third quarter. Now for a few business-related notes, beginning with UroLift. During Q3, we provided training to 124 urologists. There's still a lot of enthusiasm for UroLift, and since we've trained more than 355 physicians so far this year, we're still on track to hit our 2021 goal of training 450 to 500 urologists. Moving on to what we're doing on the consumer marketing side. We still see direct-to-consumer efforts as a catalyst for UroLift in the U.S. that will play out over multiple years. We've kept putting money behind our DTC campaign to get things ready for elective procedures to pick back up, and we'll continue that investment during Q4. We just received a bronze award for the best new branded TV campaign from a DTC standpoint, which is a significant achievement considering there were 13 finalists. UroLip continues to draw a lot of search traffic, and that level sits far ahead of what other minimally invasive BPH options generate, with most surveys of urologists still showing that patients come in requesting the UroLift System. Turning to UroLift 2, our rollout across the United States is still fully underway. At the AUA meeting in September, we officially introduced both this product and the UroLift ATC to the wider urology community. Thanks to its edge in tissue compression, a smaller storage footprint, and greater manufacturing capacity, we are in a strong position to move most physician customers over to UroLift 2 by the close of 2022. UroLift 2 keeps playing a key role in driving our margins. Once the revenue base has been completely converted, we're still on track to deliver 400 basis points of gross margin expansion for UroLift. Turning to Japan, we continue to make progress toward bringing UroLift to market commercially before too long. Recently, the three biggest urology societies in Japan came to an agreement on guidelines for UroLift's use, which is an encouraging development. As for reimbursement approval, we remain closely engaged with the MHLW, and we've gotten formal word that an expert panel will review UroLift this November. The timing of the regulatory pathway isn't something we can control, but getting that panel confirmation represents a significant milestone on the road to reimbursement in Japan, and it's one of the last steps in that process. Our baseline assumptions haven't changed — we still expect the commercial ramp to start in 2022. With a $2 billion TAM, Japan continues to be a key long-term opportunity for UroLift, and we're looking forward to the launch ahead. Our expectation remains that sales in the region will ramp similarly to how they did in the U.S., in a market that's 1/3 the size. Beyond Japan, our international regulatory and commercialization work for UroLift is still going strong. Turning to another encouraging development, our initial commercial efforts in Brazil have us excited. Although our plan had been to launch there toward the end of 2022, we were able to move faster and ran a restricted market release during the latter part of 2021's third quarter. Training a chosen group of key opinion leaders has gone well, and the inaugural UroLift procedures have now been performed in hospital as well as office environments.

Liam Kelly

executive
#4

Even though it's still early days and the market needs time to mature, Brazil continues to be a key geography for us as we grow UroLift beyond the U.S., and what we've seen so far is pretty encouraging. Now, on the reimbursement side here in the U.S., just to remind everyone, CMS came out with its proposed physician fee schedule for calendar 2022 on July 13, 2021. Under that proposed rule, reimbursement would take a negative hit for about 600 procedures done in physicians' offices spanning a wide variety of surgical specialties, with an outsized effect on device-intensive procedures like UroLift. During the public comment period, Teleflex gave CMS a thorough response laying out where we stand on the proposed rule; our view is that these changes to the physician fee schedule would restrict health care access for Medicare patients and push procedures toward sites of service that cost more. Teleflex, together with many other stakeholders, has called on CMS to hold off on implementing the proposed physician fee schedule until more analysis can be done, because of the unintended consequences of the route currently proposed; we expect the final rule to come out in November, which matches historical timing. Moving to Vascular. We're happy with how our recently launched Arrow ErgoPack kit has performed, bringing in more than $5 million of revenue in the third quarter. Among other enhancements, the new kit configuration for our CVC catheters features a nitinol guidewire that resists kinking, an improvement clinicians see as beneficial. With our leading market share in CVCs, this launch is a trade-up strategy that generates incremental gross profit dollars and helps us maintain our dominant market leadership position in CVCs. Finally, regarding our acquisition of Z-Medica, which closed in December of 2020. Integration of Z-Medica is still running slightly ahead of our internal milestones, and we're pleased with the progress being made. When it comes to possible label expansion opportunities for the hemostat portfolio, we've finished patient enrollment in a 231-patient IDE study, evaluating how QuikClot Control+ hemostatic devices perform for mild-to-moderate bleeding in cardiac procedures versus standard goals. Once the study is complete, we plan to file a 510(k) for expanded use of QuikClot Control+; that wraps up my prepared remarks. At this point I'd like to hand the call over to Tom for a more detailed review of our third quarter financial results. Tom?

Tom Powell

executive
#5

Appreciate that, Liam, and hello everyone on the call. Since we've already gone over how the top line performed, my starting point will be gross profit. Adjusted gross margin came in at 59.5% during the third quarter, which represents a 230 basis point gain over the same period a year ago. Product and regional mix, gains from cost improvement programs, plus favorable pricing, M&A and foreign exchange effects all contributed to that year-over-year gross margin rise, with raw material and distribution inflation providing a partial offset. For Q3, adjusted operating margin came in at 28.5%, which is 340 basis points higher than the prior-year period. The improvement was driven by the gross margin increase and tight cost control, though it was partly offset by deliberate business investment. Net interest expense totaled $11.8 million this quarter, compared with $16.4 million during last year's same period. The drop versus last year comes from savings related to redeeming the 2026 notes, and it also reflects the impact of reducing debt using proceeds from the respiratory divestiture plus cash from operations. In Q3 of 2021, our adjusted tax rate was 11.3%, compared with 7% the year before. The rise in that adjusted tax rate year over year stems mainly from a smaller benefit related to stock-based compensation than we saw in the prior year period. On the bottom line, adjusted earnings per share for the third quarter rose 26.7% to $3.51. That figure includes an estimated favorable foreign exchange impact of roughly $0.13 per share compared with last year. Now to a few balance sheet and cash flow items. Cash flow from operations year-to-date came to $450.5 million, versus $241.5 million in the same period a year ago, which works out to a $209 million year-over-year improvement. That gain was primarily attributable to better results from operations, lower payments tied to contingent consideration, decreased outlays for payroll and benefits, and money received through the manufacturing supply agreement we have with Medline. Now turning to the balance sheet, our financial standing remains strong. We finished the third quarter of 2021 with $481.2 million in cash, up from $375.9 million when the fourth quarter of 2020 came to a close. As noted earlier, during July we made a $259 million payment against our revolving credit facility, using mostly money from the first closing of the respiratory business divestiture. When the third quarter ended, the amount drawn on the revolver came to $342 million, and net leverage was approximately 2x. Let's move on now to what's new with the 2021 outlook we gave you. Starting on the top line: for constant currency revenue growth this year, our revised range is 8% to 9% versus a year ago, whereas we previously told you 8.5% to 9.75%. What's behind the change is that our diversified portfolio keeps delivering benefits, but UroLift sales are coming in lower, since elective surgical procedure volumes are bouncing back at a slower pace than we had built into that earlier 2021 financial guidance. As for currency, our assumption is unchanged: foreign exchange rates should still add a 2% tailwind to reported revenue in 2021. Given all that, the growth we're now projecting for as-reported revenue is 10% to 11% year-over-year, down from the 10.5% to 11.75% we cited earlier. Based on the updated outlook, the dollar range comes to between $2.791 billion and $2.186 billion. Turning to margins, we are lowering the upper bound of our 2021 adjusted gross margin forecast by 25 basis points, which brings it to 59.25% to 59.5%. On a year-over-year basis, the gross margin improvement should be driven primarily by a favorable mix of higher-margin products, such as Interventional Urology, Interventional Access and Surgical, along with manufacturing productivity initiatives and gains from the Footprint restructuring programs we previously announced, though inflation will partly offset these. Relative to what we had guided before, this revised view reflects both lower UroLift revenues and greater inflation than we had previously assumed. At Z-Medica, our outlook hasn't changed, and for 2021 it should contribute about 50 basis points to gross margin. Turning to inflation, we continue to face heavier cost pressure across raw materials and freight, plus some pressure on labor, though that's smaller. We also locked in sea freight pricing by signing lane contracts late in 2020. The majority of those deals ran out at September's close, with the remainder ending as the year wraps up. Given those shipping agreements lapsing alongside worsening inflation, our current estimate puts fourth-quarter inflationary costs at about $3 million above what we saw in the third quarter, and that effect is baked into the gross margin guidance we revised. On the adjusted operating margin line, our 2021 outlook is moving up to a range of 27.5% to 28%. Compared with what we previously told you, that's 75 basis points higher at the bottom of the range and 50 basis points higher at the top. What's driving the lift is how we've performed so far this year, though a weaker gross margin forecast is partly working against that. Going further down the P&L, interest expense should now come in at approximately $57 million, down from the $60 million to $62 million we had guided to before. Looking at 2021, the drop in net interest expense is mostly due to us paying down debt, which was made possible by money from the respiratory divestiture along with the strong cash flow we generated. On the tax side, our adjusted tax rate for 2021 is now projected at approximately 12% to 13%, compared with the earlier guidance of 13% to 13.5%. When we put all of these pieces together, we're increasing our adjusted EPS guidance for 2021 by $0.25 on both the low and high ends, bringing it to $13.15 to $13.35, which represents growth of 23.2% to 25.1% compared to last year. That wraps up what I had prepared to say. At this point I'd like to hand things back to Liam for some closing thoughts. Liam?

Liam Kelly

executive
#6

Thanks, Tom. To wrap up, I want to emphasize 3 main points from this quarter. First, thanks to our varied product lineup, Teleflex was able to achieve double-digit constant currency growth in Q3, despite COVID-19 causing more disruption than anticipated. Second, we keep moving forward with our plan to generate lasting growth throughout our diverse portfolio by investing in organic opportunities, expanding margins, and allocating capital toward M&A. Third, we lifted our 2021 earnings per share guidance, which mirrors earnings growth of 23% to 25% compared to last year. To conclude, we're pleased with how we performed overall this quarter, which was supported by our diversified range of medically necessary products. Our balance sheet remains strong, with leverage at 2x, giving us plenty of financial flexibility for our capital allocation priorities. We stay confident about what lies ahead and our capacity to keep fulfilling commitments to patients, clinicians, communities and shareholders. That wraps up my prepared remarks. At this point, I'd like to hand the call back to the operator for Q&A.

Matt Taylor

analyst
#7

The first thing I'd like to ask about is what assumptions you're making for Q4 and what you're seeing in recent trends. Based on what you said about the environment, it sounds like you're expecting stability, with some of those subdued trends from late Q3 continuing. So I just want to confirm that's right, and get any color on what you've actually observed in the early part of Q4?

Liam Kelly

executive
#8

Matt, thanks so much for the question. When we think about the fourth quarter, I believe we need to begin with the third quarter and what happened there. We're quite pleased with how revenue came in — it beat what we had expected and really shows the benefit of having a globally diversified portfolio. During the quarter, although some elective portions of our business, including UroLift, Interventional Access and Surgical, took a hit from COVID, we still hit our revenue expectations in that difficult environment and came in above our expectations on margins and EPS. In fact, EPS rose 27% in the quarter. In Q3, we delivered growth of 10.3% versus 2020 and almost 6% versus 2019. We saw strength in OEM, the Americas, EMEA and APAC. And actually, Matt, EMEA and APAC would have posted growth of 6.8% and 12.2%, respectively, if you normalize for the respiratory divestiture's impact; we also saw strength across many of our segments — Surgical Interventional, Vascular and Anesthesia. And our key growth drivers, ex-UroLift, kept delivering really solid results. MANTA grew 82%, interosseous grew 12%, PICCs grew 10%; and to your question, as the quarters went on, procedure volume didn't recover the way we originally expected, and we're not as far along on the recovery slope as we'd hoped. UroLift is clearly a deferrable procedure. And I'd view it as revenue deferred rather than revenue postponed. Procedures started getting impacted in the second half of July, but we did see improvements, Matt, in September across all of our procedure volumes that were affected; and if you look at our assumptions for UroLift specifically, and our updated assumptions for UroLift, the lower end of the range would be attributable to a flat lining up of what we saw in September through the end of the year in that regard. I don't really want to get into the specifics of Q4, Matt, because there's only one quarter left. And clearly, our guidance laid out what we're expecting in Q4 from all aspects of our business.

Matt Taylor

analyst
#9

Okay, all right. Perhaps I could ask just one thing regarding UroLift reimbursement. Clearly, we'll find out what unfolds here in the coming week or so, once the reimbursement's final outcome is known. How are you getting ready for a few of the various scenarios — whether the cut remains, whether there's a phase-in, or hopefully something better emerges? But maybe you could discuss what you believe the company would have to do under a few of those possible developments to help physicians keep their business running in the office, or shift it over to the ASC if that becomes necessary?

Liam Kelly

executive
#10

Yes. You've got that right, Matt. There's nothing new to report. As things stand today, we would anticipate the proposed ruling arriving early next month. That's the usual timing for it. We've genuinely made a strong argument supporting a CMS reconsideration of the proposed ruling. Our view is that it will restrict Medicare and Medicaid patient access to over 600 procedures. And we continue to believe the right move is to scrap the proposed ruling and work with key stakeholders on a fresh proposal. I'm not certain the investment community knows this, but more than 30,000 comments came in during the comment period. And our belief is that CMS is duly bound to weigh all comments. When the final ruling arrives — we expect to put out a press release, Matt, upon publication. We hold certain advantages relative to other minimally invasive procedures in — insofar as we have flexibility regarding size of service. The UroLift procedure is profitable, not just in the office but additionally in the ASC and the hospital. And the vast majority of urologists who perform their procedure in an office have part ownership of, or access to, an ASC and possess that degree of flexibility. So we'll await the final ruling, Matt, and after that we'll decide how we will proceed; but rest assured, plans are afoot within Teleflex to move quickly once we get the final ruling.

Cecilia Furlong

analyst
#11

Liam, I'd like to stay on the topic of UroLift and ask whether you could address procedure deferrals — both the effect DTC might have had in the quarter and the pressure from COVID. Then, looking ahead to 4Q, what were you assuming about possibly recapturing those procedures? And how do you view the current environment in terms of recapturing deferrals compared with how things unfolded back in the March, April period?

Liam Kelly

executive
#12

Sure. Let me take that last part first. My sense is that hospitals have become far more capable of adjusting to the COVID setting. And I believe they're handling the later waves considerably better. On the subject of postponed procedures and DTC — DTC — the feedback we're receiving has us quite encouraged; we expect 150% of the impressions, and through 3 quarters we're squarely on track to reach that impression count. The tally of patients who respond via the campaign keeps showing a comparable uplift, and that has us quite encouraged. Looking forward, as I mentioned before, the bottom end of the range suggests our September run rate stays flat for the rest of the year; now Cecilia, on your question about deferred procedures and other factors, we do anticipate some seasonal pickup from the deferrals and also from patients exhausting their deductible within the year, which is what we've observed in prior years. And we'd also expect to move into a normal trading environment in 2022; the market opportunity itself is unchanged. That, I'd say, is the key point. There remain 12 million men living with BPH. UroLift remains the go-to product for treating BPH. And out of those 12 million men, we've still performed only a bit more than 300,000 procedures. And of the 12,000 urologists, we've still trained only 3,000. So there's still a substantial, enormous opportunity to keep converting that — that customer base; and what we've observed ourselves is that this procedure is simply more deferrable than we'd have expected, frankly, back when we acquired the company. And nobody could have foreseen COVID in that setting either. We do believe 3 factors are affecting the product. First, appointments aren't being booked owing to state restrictions and fear of COVID. Second, I'd say, procedures already scheduled that then get canceled. And third, with a smaller impact, are the staffing shortages existing in the marketplace.

Cecilia Furlong

analyst
#13

All right, that makes sense. I also wanted to touch on the staffing shortage situation—what kind of effects have you noticed from it during 3Q, and has it become a bigger problem more recently? Beyond that, how has the site of care moved this quarter compared with what you were seeing earlier in the year, when certain cases were being redirected to the office setting? I'm just wondering whether you're observing comparable patterns. Has it continued to track more closely with your usual breakout?

Liam Kelly

executive
#14

Thanks; on that point, Cecilia, things are fairly consistent with the historical pattern we've observed. We are seeing day care procedures at hospitals come back up. That's among the trends we've noticed. As for what you asked about staffing shortages, our expectation is that these shortages will get better as we move through Q4 and into 2022. The reason is simply that physicians aren't the problem—it's largely the ancillary staff working in the office, the ASC and the hospital. Unfortunately, many of those workers were furloughed during COVID; they've been getting government checks. Those government checks started to dry up in September. So we expect a bolus of those people to re-enter the workforce in Q4 and into 2022, and we also expect to see that environment get better.

Anthony Petrone

analyst
#15

Anthony, perhaps you could give us a big-picture view regarding the shortage of nurses. We keep hearing about this on multiple calls. It appears more acute in particular ICU critical care units, yet additional specialty fields are experiencing shortfalls too. So at a broad level, how big an overall effect do you figure the lack of nurses and hospital staff had during 3Q? And should you gaze into your crystal ball toward 2022, what length of a headwind do you believe this represents? Is it temporary? Or does it extend far into the coming year? Then I'll ask a follow-up about UroLift.

Liam Kelly

executive
#16

Yes, Anthony, my sense is that location of service makes a difference, frankly; within the hospital setting, what I observe is that the staffing shortfalls stem from fatigue. Many of these individuals are simply worn out from battling COVID. Plus we've witnessed numerous retirements within nursing as well. Frankly, I believe working through that will require somewhat more time, and bringing folks back into that working setting. I suspect we might need to think about importing or speeding up nurses via the educational pipeline, or importing nurses by granting visas from other jurisdictions. Then, Anthony, if you consider the ASC and the office—especially the office—the situation there is that these workers got furloughed during COVID, since an office—a physician practicing in an office resembles a small business; thus they must attempt to safeguard their cash flow, so they furlough their staff. Those staff members dropped onto government assistance. Then that government assistance ran out around September, in that period. So my expectation is that it would likely bounce back somewhat quicker merely because those persons will wish to rejoin the labor force so they can earn income; that's my perspective. And as you may remember, Anthony, we did highlight staffing shortages during Q2. I believe we're among the relatively few companies that began spotting this trend a bit sooner.

Anthony Petrone

analyst
#17

Thanks for that. And to build on what we discussed regarding UroLift — when you consider the possibility that the market may have paused somewhat in anticipation of the reimbursement decision, do you believe that played any role in 3Q? Or was the majority of the pressure simply procedures being postponed because of delta? And, as you said before, is there a strong likelihood these get recaptured across the next couple of quarters?

Liam Kelly

executive
#18

Anthony, I'd tell you with a very high degree of confidence that CMS has nothing to do with it. The CMS ruling isn't expected until next year, and it hasn't even been announced yet; so this is entirely about COVID.

Jayson Bedford

analyst
#19

I've got a few things to ask about UroLift. I don't want to dig too deep into the weeds here, but is there anything unusual about where your UroLift revenue comes from geographically that left it more vulnerable to delta — in other words, do you have too much weight in Florida and Texas?

Liam Kelly

executive
#20

That's right. We do have a really solid footprint in Florida and Texas. For UroLift, those are definitely 2 of the markets that matter most to us; and beyond that, you need to consider Florida specifically — the population there includes a large retirement community. So the age distribution of men in that region clearly turns it into a meaningful market for us. What I'd say is that the biggest driver of — Jayson, of the — for UroLift this quarter is really just the delta variant. Plain and simple, 28 states put restrictions in place. We had figured that during September, some of those states would start scaling back their restrictions, and we had expected that in October, they'd be lifting them as well. And like I mentioned before, this is a procedure that can very easily be put off. I know 2 people myself who are in need of UroLift. And in this COVID climate, neither one of them wants to go through with it. They're holding off until things get better. So I'd call that a straightforward effect. And I'd say "deferred" is the key term here, because that's all it is — deferred; the 2 individuals I know personally will have the procedure. It's going to happen. Should it not happen in Q4, then it happens in Q1.

Jayson Bedford

analyst
#21

Okay. Okay. That's useful. As something of an associated follow-up, durable growth is clearly a priority for the group here, and the discussion will shift toward how much sustainable growth this business is able to deliver. UroLift clearly sits at the center of that discussion. So it doesn't seem as though your thinking on the end market has shifted, yet you brought up normalized growth a handful of times when talking about UroLift. So I'm just wondering, what does normalized growth mean for UroLift?

Liam Kelly

executive
#22

So the way I'd think about it is that I'd picture us entering a more normalized growth mode, once we're past COVID. This is purely a COVID effect on the business. I'm with you on your mention of durable growth. And let's think about it for a moment. We posted 10.3% growth in the third quarter, which is a terrific outcome given the conditions we're operating in. We generated 27% earnings per share growth in the third quarter. And when you get into the fourth quarter, I'm going to measure us against 2019, since for me that's a better base year. We posted 6% growth in Q3 versus 2019. In Q4, the growth implied at the midpoint of our range is high single digits. So we're demonstrating acceleration relative to 2019. So I believe that even with COVID going on, the progress of a diversified portfolio is letting us put up genuine positive growth alongside genuinely substantial earnings power because of that. As for your question about the durable, what counts as durable growth for UroLift, clearly, we'll provide guidance once we're through the fourth quarter. I want to see how the fourth quarter unfolds. I'm watching this new variant that has emerged in the U.K; and in Israel. I really want to ensure that, that doesn't turn into a problem and turn into delta part 2 as we move through the fourth quarter. But I'm with you, the end markets are unchanged. The strength of our position in those end markets is unchanged, and the clinical outcomes of the product are unchanged. It is the best product in the market. And once we're past COVID, we'll return to normalcy.

Drew Stafford

analyst
#23

Drew here, filling in for Matthew. I'd like to touch on UroLift and DTC for a moment. In your deck, you say you anticipate doubling impressions across 2020 and 2021, yet your revenue is clearly trailing far behind that rate. COVID is plainly a major factor there, I think that goes without saying. Still, do you have any read on where those patients are ending up right now? Are they making it into the doctor's office and being seen, with procedures pushed back because of COVID? Or are they running into logistical hurdles along the way?

Liam Kelly

executive
#24

Thanks. What we know for certain is that they are visiting the doctor's office. We know this since we're the ones sending them to those physicians, so that doctor is now managing their care. Once again, the effect is purely COVID. There are restrictions across 28 states. Quite frankly, you have people who aren't at ease coming in for a procedure. That's the effect. One data point I believe matters for investors to grasp is that a huge share of our champions sit in the office and the ASC. And nearly all of those champions provide just a single minimally invasive option for treating BPH, which is UroLift. So when we put money behind DTC and route patients to those physicians with the strongest clinical results, those doctors almost always offer only UroLift. That's the reason we feel a heightened degree of confidence about carrying on with our DTC. I'd also note that given the investment we're making, our impression expectation is 150%. Through 3 quarters of the year, we're well on track to hit that impression level. So DTC has us very encouraged. The engagement has us very encouraged. And earning the bronze award for the advertisement itself was nice as well.

Drew Stafford

analyst
#25

That's useful. To build a bit further on what was just discussed, regarding how the competitive field looks. You frequently mention solid momentum with Rezum, and Olympus bringing out new offerings in this area. I realize you described share as having held steady, but I'm curious whether your sales reps are running into any of those other offerings in this area. Also, do you have any read on whether your customers are examining some of the more recent offerings?

Liam Kelly

executive
#26

I'd suggest reading those remarks carefully, since they merge 2 products within that remark. And when we look at the data, it's clear we aren't giving up share. It isn't a matter of whether, we know we aren't giving up share. Looking at the claims data, market share comes across as stable, and UroLift keeps its leading spot in the minimally invasive treatment of BPH; therefore, in my view this is a COVID question, not one about competition.

Matthew Mishan

analyst
#27

I'd like to shift what we're discussing to the margin area — gross margin and operating margin. Tom, I believe you described how you pulled off what was clearly a miraculous feat by securing free contracts back in December of last year. Nice work pulling that off. But those arrangements are basically finished being utilized now. What's the right way for us to frame the headwind we'll face in Q4 and then through 2022 from that extra freight and logistics cost, plus the delayed materials costs that flow into your figures as we go along?

Tom Powell

executive
#28

Sure. What I'd say is that because we locked those contracts in, we managed to avoid a meaningful amount of expense across 2021. Like we said, several of those agreements ran out at September's close, and others ran out when December ended, so there is some elevated inflation hitting us in Q4. I mentioned $3 million in total. Most of that stems from higher freight costs, coming both from the sea freight contracts ending and simply from broader logistics inflation going up. That carries into 2022 where inflation is concerned — based on how we see things at this moment, if expenses hold steady, or rates hold steady, we'll experience elevated inflation across 2022 in our freight volume. Naturally, we'll share more specifics when we give guidance for the year, and we'll know better how rates appear to be moving and if we think there'll be any recovery next year.

Matthew Mishan

analyst
#29

Great. Now regarding reimbursement in Japan for UroLift — since you're set to appear at the meeting now, had you originally been on the schedule back in September, and they passed on reviewing it, or did they review it and push it to November? Why exactly did it get pushed back an additional 2 months?

Liam Kelly

executive
#30

Actually, it hasn't been pushed back 2 months. What happens is they notify companies and assign a date when they'll conduct the review; we received ours, and that date was November. Honestly, we had expected October, but it came out as November, and we're genuinely pleased they'll be looking at it at that point; that's a $2 billion market. It represents a fantastic opportunity for us. The pre-market efforts are already completed in the marketplace, and we expect to ramp throughout 2022; additionally, our original guidance included no revenue from it in Q4. So we're feeling quite encouraged; and Brazil encourages us as well. We're entering Brazil far sooner than we had expected. We believe that will be a strong market for us as well. A limited market launch has already been carried out. We've traveled there. We've even trained a number of surgeons. Proctors are already trained in the region. And we feel truly positive about Japan and UroLift alike, and we feel very positive about taking UroLift international into the global marketplace, which offers an opportunity just as large as the U.S. market once overseas ramping begins.

Mike Matson

analyst
#31

I'd like to build on what was asked earlier regarding inflation. Among med tech firms, yours is one of the rare ones that has historically managed to secure favorable pricing. If necessary, do you figure you might counter a portion of that inflation through further price hikes, delivery fees, or similar measures?

Liam Kelly

executive
#32

Mike, I appreciate you raising that. Put simply, absolutely. During the first 3 quarters of this year, our pricing has been favorable. Like you, I believe we're among a small group of businesses capable of achieving favorable pricing. To counter part of the inflation we've encountered, we've implemented some increases this year. Our margin improvement so far shows that clearly. In an environment with rising inflation, you can observe how strongly we're performing on margin. When we reach next year, we'll address next year. Still, our expectation would be to counter a portion of the inflation through higher prices. Delivery fees prove more difficult to put in place. Customers dislike them. From where I sit, it's preferable to simply treat this as a direct price increase.

Mike Matson

analyst
#33

All right, understood. Next, I'd like to ask about EZPlaz. From what I recall, during your previous discussion of this, you mentioned that you believed an approval might come through before this year wraps up. Is that accurate? And does that remain your view?

Liam Kelly

executive
#34

Regrettably, the timing isn't something I can influence at this point, since the FDA has it; our submission has been filed. We keep working with them. For the FDA, this is unexplored territory. This is — a biologic of this kind has never received their approval previously. Yet they keep working with us. They keep being cooperative. And clearly, Mike, we'll bring the investment community up to date the moment we have any news regarding it.

Larry Keusch

executive
#35

Appreciate it, operator, and thanks to all of you who took part in today's call. That brings the Teleflex Incorporated Third Quarter 2021 Earnings Conference Call to a close.

Operator

operator
#36

That wraps up the question portion for today. With that, we're closing out this conference call. We appreciate everyone joining us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.